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15• 2,6-Diacetylpyridine bis(4N-tolylthiosemicarbazonate) palladium(II) and platinum(II) complexes
16• These complexes exhibit high cytotoxic activity in MCF-7 tumor cells and moreover are able to circumvent cisplatin resistance in A2780cisR cells.
17• All complexes are in vitro non-toxic against normal LLC-PK1 renal cells at the concentration range tested.
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37Preparation and characterization of four novel 2,6-diacetylpyridine bis(4N-tolyl thiosemicarbazonato)
palladium(II) and platinum(II) complexes, [PdL1––2] and [PtL1–2], are described. All compounds have been
characterized by elemental analysis and by IR and NMR spectroscopy, and the crystal and molecular struc-
tures of complexes [PdL2] and [PtL2] have been determined by a single crystal X-ray diffraction. The ligands
act as dianionic tetradentate donors coordinating to the metal center in a square planar geometry through
the Npyridinic atom and the Niminic and the S atoms from one thiosemicarbazone arm, the fourth coordination
position is occupied by the Nhydrazinic of the other arm. The new compounds synthesized have been evaluated
for antiproliferative activity in vitro against NCI-H460, HepG2, MCF-7, A2780 and A2780cisR human cancer
cell lines. The cytotoxicity data suggest that [PdL1], [PdL2] and [PtL2] may be endowed with important
antitumor properties since they are capable of not only circumventing cisplatin resistance in A2780cisR
cells but also exhibiting high antiproliferative activity in breast cancer MCF-7 cells. Subsequent toxicity
study, in LLC-PK1 cells, has also been carried out and shows that none of these compounds are in vitro
toxic in the tested concentration range.
© 2013 Published by Elsevier Inc.38961
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801. Introduction
Platinum metallo-drugs are among the most effective agents for
the treatment of cancer however its clinical utility is restricted due
to the frequent development of drug resistance, the limited spectrum
of tumors against which these drugs are active and severe normal tis-
sue toxicity being the nephrotoxicity an important side effect which
interferes with their therapeutic efﬁciency [1–5].
These disadvantages have driven the development of improved
platinum-based anticancer drugs different from the traditional cisplatin
structure and which could probably have different DNA-bindingmodes
as well as exhibit different biological proﬁles [6–10].
In this regard and taking into account that one of the mechanisms
inducing the nephrotoxicity is due to the inactivation of some enzymes
because of the reaction between platinum ions and sulfur containing
proteins, an active area of research focuses on the synthesis of chelate
platinum(II) complexes bearing nitrogen and sulfur mixed donor
atoms, which should prevent the adverse reaction described [11,12].
Thiosemicarbazones (R1R2C_N\NH\C(S)\NR3R4) are an im-
portant and versatile type of ligands due to the potential donor81
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Palladium(II) and platinum(I
m. (2013), http://dx.doi.org/atoms that they possess, among which sulfur is of paramount impor-
tance in the metal-ligand linkage. Particularly, compounds in which
the thiosemicarbazone side-chain is attached in α position to an N-
heterocyclic ring, namely α-N-heterocyclic thiosemicarbazones
(N-TSCs), are strong metal chelating agents and moreover some of
them have showed antineoplastic activity by themselves. It has
been demonstrated that the biochemical mechanism of action in-
volves, among others, ribonucleotide reductase (RR) inhibition and
non-covalent DNA binding [13–19].
On the other hand, the pyridine ring itself is a part of many natural
and synthetically prepared pharmaceuticals. In addition, the pyridine
moiety plays a signiﬁcant role in many biological processes like nico-
tinamide adenine dinucleotide phosphate NADP or vitamin B6
[20,21].
Keeping in view the above observations and as part of our sys-
tematic investigation on the coordination chemistry of thiosemi-
carbazone derivatives we planned to construct a series of α-N-
heterocyclic bis(thiosemicarbazone) platinum(II) and palladium(II)
complexes bearing 2,6-diacetylpyridine as heterocyclic ring speciﬁcally
using 2,6-diacetylpyridine bis(4N-ortho-tolylthiosemicarbazone), H2L1,
and 2,6-diacetylpyridine bis (4N-para-tolyllthiosemicarbazone), H2L2,
ligands (Scheme 1).
Thus, this work is aimed to describe the synthesis and chemical
characterization of four new 2,6-diacetylpyridine bis(4N-tolylthiosemi-
carbazonato) palladium(II) and platinum(II) complexes. The cytotoxicI) bis(thiosemicarbazone) complexes of the 2,6-diacetylpyridine series
10.1016/j.jinorgbio.2013.04.005
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Scheme 1. General structure of diacetylpyridine bis(4N-tolylthiosemicarbazone)
ligands.
2 A.I. Matesanz et al. / Journal of Inorganic Biochemistry xxx (2013) xxx–xxxactivity of the new compounds synthesized, their parent ligands and cis-
platin (assumed as the reference antitumor drug) against ﬁve human
cancer cell lines: NCI-H460 (non-small cell lung cancer), HepG2 (hepato-
cellular carcinoma), MCF-7 (breast cancer), A2780 and A2780cisR
(epithelian ovarian cancer) has been studied. In addition toxicity studies,
on normal renal LLC-PK1 cells, have been carried out as an attempt to pro-
vide an insight into the pharmacological properties of these compounds.
The single-crystal X-ray structures of [PdL2], [PtL2] and H2L1 are also
discussed.
2. Experimental
2.1. Measurements
Elemental analyses were performed on a LECO CHNS-932 micro-
analyzer. Fast atom bombardment (FAB) mass spectra (MS) were
performed on a VG AutoSpec spectrometer (mNBA: nitrobenzyl alcohol
matrix). All cited physical measurements were obtained by the Servicio
Interdepartamental de Investigación (SIDI) of the Universidad Autónoma
de Madrid.
Melting points were determined with a Stuart Scientiﬁc SMP3paratus. Infrared spectra (KBr pellets) were recorded on a Bomen–105 lson spectrophotometer (4000–400 cm−1). Electronic spectra 106 recorded on a Thermo Scientiﬁc Evolution 260 Bio UV–visible 107 (UV–pectrophotometer.
2.2. Materials
Solvents were puriﬁed and dried according to standard proce-
dures. Hydrazine hydrate, 2,6-diacetylpyridine, ortho-tolyl isothiocy-
anate, para-tolyl isothiocyanate, PdCl2(PPh3)2 and PtCl2(PPh3)2 were
commercially available.
2.3. Synthesis of compounds
The two ligands were synthesized following general procedures as
described in references [22,23]. In support of analytical and spectro-
scopic data, consistent with those previously reported, the X-ray
structure of H2L1 ligand has been determined here for the ﬁrst time.
Mononuclear neutral complexes of formulae [ML1–2] whereM = Pd,
Pt were obtained by reaction of the corresponding MCl2(PPh3)2 metallic
salt with the desired ligand, in toluene, in the presence of Et3N, in
1:1 molar ratios. The reaction mixture was stirred for 2 h at room tem-
perature. The resulting orange solution was ﬁltered and left to stand at
ambient temperature for two days. The solid formed was ﬁltered,Please cite this article as: A.I. Matesanz, et al., Palladium(II) and platinum(I
with high cytotoxic activity..., J. Inorg. Biochem. (2013), http://dx.doi.org/washed several timeswith hotwater, crystallized fromDMSO and ﬁnally
dried in vacuo.
2.3.1. [PdL1]
Yield (70%), mp 232 °C (decomposes). Elemental analysis found,
C, 50.50; H, 4.30, N, 15.95; S 10.55; C25H25N7S2Pd requires C, 50.40;
H, 4.30, N, 15.85; S 10.50%. MS (FAB+ with mNBA matrix) m/z
596.07 for [PdL1 + H]+. IR (KBr pellet): n/cm−1 3323 (s, NH); 1582
(s, CN); 1569 (s, CN-thioamide I); 853 (w, CS-thioamide IV); 618,
430 (pyridine ring). 1H NMR (300 MHz, d6-DMSO, ppm), δ = 10.45,
9.40 [s, 4NH, 1H]; δ = 8.40 [d, CH-pyridine, 2H]; 8.25 [t, CH-
pyridine, 1H]; δ = 7.20–7.00 (m, aromatic-thiosemicarbazide, 8H);
δ = 2.50 (s, CH3-thiosemicarbazide, 6H); δ = 2.25 (s, CH3-
diacetylpyridine, 6H). UV/VIS (DMSO): λ/nm 343, 422, 486.
2.3.2. [PtL1]
Yield (55%), mp 216 °C (decomposes). Elemental analysis found, C,
42.35; H, 3.95; N, 13.00; S, 12.25; C25H25N7S2Pt · DMSO requires C,
42.45; H, 4.30; N, 12.85; S 12.60%. MS (FAB+ with mNBA matrix) m/z
683 for [PtL1 + H]+. IR (KBr pellet): n/cm−1 3353 (s, NH); 1586 (s,
CN); 1523 (s, CN-thioamide I); 849 (w, CS-thioamide IV); 617, 428
(pyridine ring). 1H NMR (300 MHz, d6-DMSO, ppm), δ = 10.75, 9.50
[s, 4NH, 1H]; δ = 8.50 [d, CH-pyridine, 2H]; 8.00 [t, CH-pyridine, 1H];
δ = 7.35–7.10 (m, aromatic-thiosemicarbazide, 8H); δ = 2.75 (s,
CH3-thiosemicarbazide, 6H); δ = 2.25, 2.20 (s, CH3-diacetylpyridine,
3H). UV/VIS (DMSO): λ/nm 341, 395, 420.
Based on the characterization data, this compound can also be
synthesized by reaction of K2PtCl4 with H2L1 ligand as we described
recently [22].
2.3.3. [PdL2]
Yield (35%), mp 226 °C (decomposes). Elemental analysis found, C,
46.80; H, 4.85;N, 13.90; S, 13.50; C25H25N7S2Pd · DMSO · H2O requires
C, 47.00; H, 4.80; N, 14.20; S 13.90%. IR (KBr pellet): n/cm−1 3291 (s,
NH); 1595 (s, CN), 854, 817, 808 (w, CS-thioamide IV band); 638, 419
(pyridine ring). 1H NMR (300 MHz, d6-DMSO, ppm), δ = 10.60, 10.00
[s, 4NH, 1H]; 8.40 [t, CH-pyridine, 1H]; δ = 8.25, 8.10 [d, CH-pyridine,
2H]; δ = 7.55–7.10 (m, aromatic-thiosemicarbazide, 8H); δ = 2.70,
2.60 (s, CH3-thiosemicarbazide, 6H); δ = 2.25 (s, CH3-diacetylpyridine,
6H). UV/VIS (DMSO): λ/nm 268, 293, 405.
Recrystallization from DMSO led to the isolation of orange crystals
of [PdL2]·0.5DMSO that were suitable for X-ray-diffraction.
2.3.4. [PtL2]
Yield (55%), mp 234 °C (decomposes). Elemental analysis found, C,
41.60; H, 3.90; N, 13.50; S, 9.10; C25H25N7S2Pt · 2H2O requires C,
41.75; H, 4.05; N, 13.65; S 8.90%. MS (FAB+ with mNBA matrix) m/z
683 for [PtL2 + H]+. IR (KBr pellet): n/cm−1 3250 (s, NH); 1593 (s,
CN), 850, 804 (w, CS-thioamide IV band); 638, 420 (pyridine ring). 1H
NMR (300 MHz, d6-DMSO, ppm), δ = 10.60, 10.15 [s, 4NH, 1H]; δ =
8.50 [d, CH-pyridine, 1H]; 7.80 [t, CH-pyridine, 1H]; δ = 7.45 [d,
CH-pyridine, 1H]; δ = 7.40–7.20 (m, aromatic-thiosemicarbazide,
8H); δ = 2.50 (s, CH3-thiosemicarbazide, 6H); δ = 2.30 (s, CH3-
diacetylpyridine, 6H). UV/VIS (DMSO): λ/nm 255, 310, 400.
Recrystallization from DMSO led to the isolation of dark red crys-
tals of [PtL2]·DMSO that were suitable for X-ray-diffraction.
2.4. Crystallography
Data were collected on a Bruker X8 APEX II CCD (compounds H2L1,
PdL2and PtL2). Crystallographic data and selected interatomic dis-
tances and angles are listed in Table 1. For all compounds, the soft-
ware package SHELXTL was used for space group determination,
structure solution, and reﬁnement [24]. The structures were solved
by direct methods, completed with difference Fourier syntheses,
and reﬁned with anisotropic displacement parameters.I) bis(thiosemicarbazone) complexes of the 2,6-diacetylpyridine series
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Table 1t1:1
t1:2 Crystal data and structure reﬁnement for H2L1, [PdL2] and [PtL2] compounds.
t1:3 H2L1·DMSO·0.5H2O [PdL2]·0.5DMSO [PtL2]·DMSO
t1:4 Molecular formula C27H34N7O1.5S3 C26H28N7O0.5PdS2.5 C27H31N7OPtS3
t1:5 Formula weight 576.79 633.10 760.86
t1:6 Temperature (K) 100 (2) 100 (2) 100 (2)
t1:7 Wavelength (Å) 0.71073 0.71073 0.71073
t1:8 Crystal system Monoclinic Monoclinic Monoclinic
t1:9 Space group C2/c P21/c P21/c
t1:10 a (Å) 35.225 (3) 14.0884 (13) 13.9098 (12)
t1:11 b (Å) 7.4795 (7) 7.6059 (6) 7.4227 (7)
t1:12 c (Å) 21.9895 (16) 27.227 (2) 27.182 (2)
t1:13 α/° 90 90 90
t1:14 β/° 98.215 (3) 91.119 (5) 90.439 (4)
t1:15 γ/° 90 90 90
t1:16 Volume (Å3) 5734.0 (8) 2917.0 (4) 2806.4 (4)
t1:17 Z 8 4 4
t1:18 Density (calculated) (g/cm3) 1.336 1.442 1.801
t1:19 Absorption coefﬁcient (mm−1) 0.295 0.845 5.259
t1:20 F(000) 2440 1292 1504
t1:21 Crystal size (mm3) 0.40 × 0.15 × 0.10 0.24 × 0.04 × 0.04 0.23 × 0.02 × 0.02
t1:22 Index ranges −47 ≤ h ≤ 47, −10 ≤ k ≤ 10,
−29 ≤ l ≤ 29
−16 ≤ h ≤ 16, −9 ≤ k ≤ 9,
−32 ≤ l ≤ 31
−16 ≤ h ≤ 16, −8 ≤ k ≤ 8,
−31 ≤ l ≤ 29
t1:23 Reﬂections collected 35398 39446 9556
t1:24 Independent reﬂections 7429 [R(int) = 0.0629] 5330 [R(int) = 0.1624] 4195 [R(int) = 0.062]
t1:25 Data/restraints/parameters 7429/0/358 5330/1/352 4195/0/328
t1:26 Goodness-of-ﬁt on F2 1.002 0.999 1.011
t1:27 Final R indices [I > 2σ(I)] R1 = 0.0571, wR2 = 0.1598 R1 = 0.09, wR2 = 0.2526 R1 = 0.085, wR2 = 0.247
t1:28 R indices (all data) R1 = 0.1016, wR2 = 0.1970 R1 = 0.2039, wR2 = 0.3237 R1 = 0.1403, wR2 = 0.2891
t1:29 Largest diff. peak and hole, e. Å−3 1.596 and −0.463 1.399 and −1.015 2.156 and −2.641
3A.I. Matesanz et al. / Journal of Inorganic Biochemistry xxx (2013) xxx–xxxCCDC 918229, 918230 and 923814 contain the supplementary crys-
tallographic data for compounds H2L1, [PtL2] and [PdL2] respectively.
These data can be obtained free of charge at www.ccdc.cam.ac.uk/
conts/retrieving.html [or from the Cambridge Crystallographic Data
Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44-1223/
336-033; e-mail: deposit@ccdc.cam.ac.uk].225
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2492.5. In vitro antiproliferative activity
The human cancer cells A2780, A2780cisR and NCI-H460 were
grown in RPMI-1640 medium supplemented with 10% fetal bovine
serum (FBS) and 2 mM L-glutamine in an atmosphere of 5% CO2 at
37 °C. The human cancer cells MCF-7 were grown in EMEM (mini-
mum essential medium, Eagle) with 2 mM L-glutamine and Earle's
BSS (adjusted with 1.5 g/L NaHCO3, 0.1 mM nonessential amino
acids and 1 mM sodium pyruvate) and supplemented with 10% FBS
and 0.01 mg/mL bovine insulin in an atmosphere of 5% CO2 at 37 °C.
The human cancer cells Hep-G2 were grown in EMEM medium
supplemented with 10% FBS in an atmosphere of 5% CO2 at 37 °C.
Cell proliferation was evaluated by the sulforhodamine B assay.
Cells were plated in 96-well sterile plates at a density of 1.5 · 104
(for NCI-H460), 1 · 104 (for MCF-7 and Hep-G2) or 4 · 103 (for
A2780 and A2780cisR) cells per well with 100 μL of medium and
were then incubated for 24 h. After attachment to the culture surface
the cells were incubated with various concentrations of the com-
pounds tested freshly dissolved in DMSO (1 mg/mL) and diluted in
the culture medium (DMSO ﬁnal concentration 1%) for 48 h (for
NCI-H460 and Hep-G2) or 96 h (for A2780, A2780cisR and MCF-7).
The cells were ﬁxed by adding 50 μL of 30% trichloroacetic acid
(TCA) per well.
The plates were incubated at 4 °C for 1 h and then washed ﬁve
times with distilled water. The cellular material ﬁxed with TCA was
stained with 0.4% sulforhodamine B dissolved in 1% acetic acid for
10 min. Unbound dye was removed by rinsing with 0.1% acetic acid.
The protein-bound dye was extracted with 10 mM unbuffered Tris
base for determination of optical density (at 515 nm) in a Tecan
Ultra Evolution spectrophotometer.Please cite this article as: A.I. Matesanz, et al., Palladium(II) and platinum(I
with high cytotoxic activity..., J. Inorg. Biochem. (2013), http://dx.doi.org/The normal cells (LLC-PK1) were grown in 199 medium
supplemented with 3% FBS and 1.5 g/L of sodium bicarbonate in an
atmosphere of 5% CO2 at 37 °C. Cell proliferation was evaluated by
the sulforhodamine B assay. Cells were plated in 96-well sterile plates
at a density of 1 · 104 cells per well with 100 μL of medium and were
then incubated for 24 h. After attachment to the culture surface the
cells were incubated with various concentrations of the compounds
tested freshly dissolved in DMSO (1 mg/mL) and diluted in the cul-
ture medium (DMSO ﬁnal concentration 1%) for 48 h at 37 °C. The
cells were ﬁxed by adding 50 μL of 30% TCA per well. The plates
were treated as described above for cancer cells.
The effects of compounds were expressed as corrected percentage
inhibition values according to the following equation:
% inhibition ¼ 1− T=Cð Þ½   100
where T is the mean absorbance of the treated cells and C the mean
absorbance in the controls.
The inhibitory potential of compounds was measured by calculat-
ing concentration–percentage inhibition curves, these curves were
adjusted to the following equation:
E ¼ Emax= 1þ IC50=Cð Þn
 
where E is the percentage inhibition observed, Emax is the maximal ef-
fects, IC50 is the concentration that inhibits 50% of maximal growth, C
is the concentration of compounds tested and n is the slope of the
semi-logarithmic dose–response sigmoid curves. This non-linear
ﬁtting was performed using GraphPad Prism software [25].
For comparison purposes, the antiproliferative activity of cisplatin
was evaluated under the same experimental conditions. All compounds
were tested in two independent studieswith triplicate points. These ex-
periments were carried out at the Unidad de Evaluación de Actividades
Farmacológicas de Compuestos Químicos (USEF), Universidad de Santi-
ago de Compostela.I) bis(thiosemicarbazone) complexes of the 2,6-diacetylpyridine series
10.1016/j.jinorgbio.2013.04.005
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Table 2 t2:1
t2:2Selected bond distances (Å) for H2L1.
t2:3H2L1
t2:4S(1)\C(16) 1.678 (3)
t2:5S(2)\C(15) 1.683 (3)
t2:6C(2)\N(2) 1.427 (4)
t2:7C(8)\N(1) 1.421 (3)
t2:8C(15)\N(1) 1.344 (3)
t2:9C(15)\N(3) 1.369 (3)
t2:10C(16)\N(2) 1.333 (3)
t2:11C(16)\N(5) 1.362 (4)
t2:12C(17)\N(4) 1.290 (3)
t2:13C(23)\N(6) 1.293 (4)
t2:14N(3)\N(4) 1.374 (3)
t2:15N(5)\N(6) 1.371 (3)
4 A.I. Matesanz et al. / Journal of Inorganic Biochemistry xxx (2013) xxx–xxx3. Results and discussion
3.1. Synthesis and spectroscopic characterization
Reaction of 2,6-diacetylpyridine bis(4N-tolylthiosemicarbazone)
ligands with equimolar amount of MCl2(PPh3)2, where M = Pd(II)
or Pt(II), led to the isolation of the neutral mononuclear complexes
[PdL1–2] and [PtL1–2] in which the corresponding bis(thiosemicarbazone)
behaves as dianionic ligand with deprotonation of hydrazinic (2NH) pro-
tons and [NNNS] donor set.
The new palladium(II) and platinum(II) complexes obtained are
stable to air and moisture and were characterized by elemental anal-
ysis and FAB+ spectrometry and spectroscopic studies (selected IR
and UV–VIS bands are listed in the Experimental section).
The infrared spectral bandsmost useful for determining themode of
coordination of the ligands are the υ(C_N) iminic and υ(C_S)
thioamide IV vibrations. These bands are shifted to lowerwavenumbers
in the spectra of the complexes suggesting coordination of the imine ni-
trogen and sulfur atoms. The pyridine nitrogen also appears to be in-
volved in coordination based on the in-plane and out-of-plane ring
deformation bands which show shift to upper wavenumbers and fairly
low intensity [26].
The electronic absorption spectra of [PdL2] and [PtL2] complexes
exhibit three intense bands in the region 250–485 nm, the two
most energetic can be ascribed to ligand-centered n → π* and
π → π* transitions while the third is assigned to a combination of li-
gand to metal (LMCT) and metal to ligand charge transfer (MLCT)
transitions. However for [PdL1] and [PtL1] complexes no transitions
that could be assigned to an n → π* type was observed in the spectra,
probably this band is covered with the more intense π → π* [27].
3.2. Description of the crystal structures
Good quality crystals suitable for single crystal X-ray diffraction
analysis were obtained for H2L1, [PdL2] and [PtL2] compounds by
recrystallization in dimethyl sulfoxide.
The molecular structure of H2L1 free ligand together with the
atomic numbering scheme is shown in Fig. 1. Crystallographic data
is shown in Table 1 and selected bond lengths are listed in Table 2.
The crystal structure ofH2L1 consists of discreteH2L1·DMSO·0.5H2O
molecules with the two thiosemicarbazone arms adopting a syn-open
arrangement in order to minimize unfavorable electronic interactions
between the two tolyl groups. Therefore to achieve the coordinative
disposition found in d8 metal complexes, syn-close conformation, a
rearrangement of the molecule structure, by twisting around the C\C
bonds adjacent to the pyridine ring, is necessary [28].
On the other hand the sulfur atom S(1) and the imine nitrogen atom
N(6) are in trans positionwith respect to the C(16)\N(5) bond and theFig. 1. Molecular struct
Please cite this article as: A.I. Matesanz, et al., Palladium(II) and platinum(I
with high cytotoxic activity..., J. Inorg. Biochem. (2013), http://dx.doi.org/same conﬁguration is observed for S(2) and N(4) with respect to the
C(15)\N(3) bond, therefore the ligand exists in E conﬁguration
which is often observed in thiosemicarbazones [29]. The C_Nimine
bonddistances of 1.290(3) and 1.293(4) are in conformitywith a formal
C_N double bond and the C_S bond distances of 1.678(3) and
1.683(3) Å, are very close to a formal C_S double bond length, these
facts conﬁrm the existence of the thiosemicarbazone groups in the
thione form, in the solid state. However, the N(3)\N(4), N(3)\C(15),
C(15)\N(1) and N(5)\N(6), N(5)\C(16), and C(16)\N(2) bond
distances are intermediate between the ideal values of corresponding
single and double bondswhich is indicative of some electron delocaliza-
tion along the thiosemicarbazide side chains.
Supramolecular association involves the water of crystallization
molecule, which forms two hydrogen bonds as hydrogen donor
(with sulfur atoms of two DMSO as acceptors) and two more as ac-
ceptor (acting the N(3) atoms of two different ligand molecules as
donor). The packing (Fig. S1, Supporting Information) suggests
weak by π–π stacking interactions (C⋯C distance about 4.1 Å) be-
tween molecules via the terminal phenyl rings.
[PdL2]·0.5DMSO and [PtL2]·DMSO were isolated as neutral com-
pounds. The most signiﬁcant parameters for these complexes are
shown in Table 1. The structures together with the atom labeling
schemes are shown in Fig. 2 and Fig. S2 (Supporting Information).
Both compounds are isostructural hence displaying nearly identical
cell parameters and crystallize in the monoclinic P21/c space group
with Z = 4.
The metal ion presents a square planar geometry being the
bis(thiosemicarbazone) ligand attached through the Npyridinic atom,
the Niminic and the S atoms from one thiosemicarbazone arm and
being the fourth coordination position occupied by the Nhydrazinic of
the other thiosemicarbazone arm generating two typical ﬁve mem-
bered (PdSCNN and PdNCCN or PtSCNN and PtNCCN) and one six
membered (PdNNCCN or PtNNCCN) chelate rings. Coordination byure of H2L1 ligand.
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Fig. 2. Molecular structure of [PdL2] complex.
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the bibliography for some d8 bis(thiosemicarbazone) complexes
[22,30–32].
It is important to note that the two thiosemicarbazone moieties
coordinate in a different fashion and so upon coordination the
bidentate-N∧S arm undergoes signiﬁcant evolution from the thione
to the thiol form which is reﬂected in C\S distance of 1.735(15) for
[PdL2]·DMSO and 1.80(2) for [PtL2]·DMSO while the monodentate-
Nhidrazinic thiosemicarbazone arm presents a shorter C\S bond length
[1.641(16) for [PdL2]·DMSO and 1.68(3) Å for [PtL2]·DMSO]. On the
other hand The C\N and N\N bond distances, listed in Table 3, are
intermediate between formal single and double bonds, pointing to
extensive delocalization over the entire 2,6-diacetylpyridine
bis(thiosemicarbazone) skeleton [33].
Inspection of the angles formed between themetal ion (M = Pd2+,
Pt2+) and the coordinated atoms shows that the metal is contained
within a slightly distorted square-planar environment. The distortion
is caused by the restricted bite angle of the N(4), N(5), S(2) donor set
as reﬂected in the S(2)\M(1)\N(5) and N(4)\M(1)\N(5) angles
(less than 90°). The angles N(4)\M(1)\N(2) and N(2)\M(1)\S(2)
are therefore greater than 90°.Table 3
Selected bond distances (Å) and angles (°) for [PdL2] and [PtL2].
[PdL2] [PtL2]
S(1)\C(18) 1.641 (16) 1.68 (3)
S(2)\C(10) 1.735 (15) 1.80 (2)
C(2)\N(3) 1.275 (17) 1.24 (3)
C(8)\N(5) 1.333 (17) 1.37 (3)
C(10)\N(6) 1.328 (18) 1.26 (3)
C(10)\N(7) 1.335 (18) 1.36 (3)
C(11)\N(7) 1.46 (2) 1.47 (3)
C(18)\N(1) 1.400 (18) 1.34 (3)
C(18)\N(2) 1.366 (17) 1.43 (3)
C(19)\N(1) 1.436 (17) 1.49 (3)
M\S(2) 2.304 (4) 2.307 (6)
M\N(2) 2.062 (12) 1.99 (2)
M\N(4) 2.017 (10) 2.04 (2)
M\N(5) 1.976 (12) 1.98 (2)
N(2)\M\N(4) 91.9 (5) 90.3 (8)
N(2)\M\N(5) 173.9 (5) 173.2 (7)
N(4)\M\N(5) 82.1 (5) 83.0 (8)
N(2)\M\S(2) 104.0 (3) 104.4 (5)
N(4)\M\S(2) 164.0 (4) 165.3 (6)
N(5)\M\S(2) 82.0 (4) 82.4 (5)
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with high cytotoxic activity..., J. Inorg. Biochem. (2013), http://dx.doi.org/In both compounds the crystal structure is stabilized by inter-
molecular hydrogen interaction involving the N(7) atom of the
bidentate thiosemicarbazone arm and the oxygen atom of DMSO sol-
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3723.3. Antiproliferative activity against tumor and normal cells
To assess the antitumor potential of the synthesized compounds,
its antiproliferative activity (in powder solid form) was tested in
vitro against a panel of human cancer cell lines containing examples
of lung (NCI-H460), breast (MCF7), liver (Hep-G2) and ovarian
(A2780 and A2780cisR) cancers. For comparison purposes, the cyto-
toxicity of cisplatin was always evaluated under the same experimen-
tal conditions.
The results indicate that the two free ligands, H2L1 and H2L2, and
platinum complex [PtL1] showed at 100 μM concentration, very low
cellular growth inhibition (b50%) and therefore had no evaluable cy-
totoxicity (IC50 > 100 μM). However [PdL1], [PdL2] and [PtL2] com-
plexes displayed high antiproliferative activity against epithelian
ovarian (A2780, cisplatin sensitive, and A2780cisR, cisplatin resistant)
and breast (MCF-7) cancer cells (Table 4). It is remarkable to note
that palladium complex [PdL1] exhibited better cytotoxic effects
against MCF-7 and A2780cisR cells than cisplatin by comparing their
IC50.
The A2780cisR cell line encompasses all of the known major
mechanisms of resistance to cisplatin: reduced drug transport, en-
hanced DNA repair/tolerance, and elevated GSH levels. The ability ofTable 4 t4:1
t4:2In vitro antiproliferative activity of the bis(thiosemicarbazone) compounds and cis-
t4:3platin, evaluated in human MCF-7 (breast cancer), A2780 and A2780cisR (epithelian
t4:4ovarian cancer) cell lines. Q2
t4:5IC50 ± SD (μM) RF
t4:6A2780 A2780cisR MCF-7 7IC50(A2780cisR)/IC50(A2780)
t4:8H2L1 >100 >100 >100
t4:9H2L2 >100 >100 > 100
t4:10[PdL1] 5.97 ± 0.06 5.80 ± 0.49 4.41 ± 0.45 0.97
t4:11[PtL1] >100 >100 >100
t4:12[PdL2] 21 ± 1 22 ± 1 48 ± 2 0.86
t4:13[PtL2] 20 ± 2 18 ± 1 44 ± 2 1.1
t4:14Cisplatin 0.83 ± 0.02 7.21 ± 0.13 8.75 ± 0.35 8.68
I) bis(thiosemicarbazone) complexes of the 2,6-diacetylpyridine series
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Table 5t5:1
t5:2 In vitro antiproliferative activity of the bis(thiosemicarbazone) compounds and cis-
t5:3 platin, evaluated in normal LLC-PK1 renal cells.
t5:4 LLC-PK1
t5:5 %Inhibition (100 μM) IC50 ± SD (μM)
t5:6 H2L1 2 >100
t5:7 H2L2 1 >100
t5:8 [PdL1] 20 >100
t5:9 [PtL1] 2 >100
t5:10 [PdL2] 1 >100
t5:11 [PtL2] 23 >100
t5:12 Cisplatin 90 6.86 ± 0.10
6 A.I. Matesanz et al. / Journal of Inorganic Biochemistry xxx (2013) xxx–xxx[PdL1], [PdL2] and [PtL2] complexes to circumvent cisplatin-acquired
resistance was conﬁrmed from the resistance factor values, RF (de-
ﬁned as IC50 in A2780cisR/IC50 in A2780) since all of them have a
much better RF than cisplatin. An RF of b2 was considered to denote
non-cross-resistance and therefore the three compounds tested are
able to circumvent cisplatin resistance [34,35].
These observations, on the ability of 2,6-diacetylpyridine
bis(4N-tolyl-tolylthiosemicarbazone) complexes to overcome cisplatin
resistance in A2780cisR cells, agree with our previous studies of
bis(4N-substituted thiosemicarbazones) derived from 3,5-diacetyl-1,2,4-
triazol heterocyclic ring [36–38].
Platinum base therapies are frequently associated with cumulative
and irreversible toxicities such as nephropathy. Therefore, in order to
investigate this possible side effect, the compounds investigated and
cisplatin were subsequently tested, in vitro, on normal renal LLC-PK1
cells in the same μM range (1–100). As showed in Table 5, all com-
pounds showed at themaximum concentration tested very low cellular
growth inhibition (b50%) and therefore had no evaluable cytotoxicity
(IC50 > 100 μM) in this normal cell line. This means that none of
these compounds are toxic, in vitro, in the tested concentration range.
4. Conclusions
A new family of Pt(II) and Pd(II) bis(thiosemicarbazone) com-
pounds incorporating the 2,6-diacetylpyridine heterocyclic ring has
been successfully prepared and characterized.
This study has identiﬁed [PdL1], [PdL2] and [PtL2] complexes as hav-
ing high antiproliferative activity since they are capable of not only
circumventing cisplatin resistance in A2780cisR cells but also exhibiting
high antiproliferative activity against breast (MCF-7) cancer cells.
Moreover, it is important to note that these compounds exhibit very
low nephrotoxicity with respect to cisplatin which conﬁrmed that
these complexes are very speciﬁc on cancer cells.
In conclusion, this study indicates that the newly synthesized
complexes valuably lead to the development of new anticancer che-
motherapeutic agents capable of retaining their activity in the
human ovarian carcinoma cell line resistant to cisplatin A2780cisR.
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